Marker Therapeutics (NasdaqCM:MRKR) FY Conference Transcript

Marker Therapeutics (NasdaqCM:MRKR) FY Conference February 25, 2026 08:00 AM ET Company ParticipantsAnthony - AssociateJuan Vera - President and CEOAnthonyGood morning, everyone, and thanks so much for joining us. I'm Anthony, an associate here at Oppenheimer, and it is my pleasure to introduce Marker Therapeutics. Marker is an immuno-oncology company focused on developing T-cell therapies using its multi-antigen recognizing or MAR-T platform. The lead program is MT-601, and it's being studied in relapse ly ...